The fixed combination of halobetasol and tazarotene topicals significantly reduced the severity of localized disease with a favorable safety profile, shows a study published in the Journal of the American Academy of Dermatology.
Three patients achieve 80-100 percent clearance of moderate-to-severe dyshidrosis of the hands and palms after treatment with dupilumab.
Symptomatic relief remains out of reach for many who suffer chronic pruritis. Without drugs specifically approved to treat chronic itch, providers and patients rely on therapies with limited efficacy. Here’s an update of two important clinical trials.
Spanish researchers have developed a scoring system to assess the severity of frontal fibrosing alopecia, a scarring form of alopecia marked by hairline recession and eyebrow loss primarily affecting postmenopausal women.
As regulatory demands and office expenses increase, insurance reimbursement seems flat or on a slow decline, says Howard Wooding Rogers, M.D.
Physicians may want to reconsider goals for the treatment of plaque psoriasis. In this study, physicians describe utilizing treat-to-target with a patient-centered approach to care for symptom relief.
As the list of treatments for plaque psoriasis grows, so does the list of adverse events associated with biologic treatment. In this article, we summarize adverse events associated with common treatments for plaque psoriasis.
Immune system modulators are changing the ways in which dermatologists treat inflammatory skin diseases. But how best to use these medications and for which skin diseases isn’t always clear.
Pediatric dermatologist Alanna Bree, M.D., left a secure position with a well-respected hospital to embark on a faith-filled professional journey. In this profile, Dr. Bree shares her story of practice, discovery and renewal.
"Plaque psoriasis is increasingly recognized as a multisystemic disease whose most common comorbidities include psoriatic arthritis, cardiovascular disease, metabolic syndrome, overweight/obesity, inflammatory bowel disease, and depression. The presence of such comorbidities affects the therapeutic choices for clinicians," researchers write in Seminars in Cutaneous Medicine and Surgery.